Dole plc Schedules First Quarter 2022 Earnings Release

DUBLIN--(BUSINESS WIRE)-- Dole plc (NYSE: DOLE) will announce its financial results for the first quarter of 2022 on Tuesday, May 24, 2022, prior to the market opening. The company’s management will host a webcast and conference call on the same day at 08:00 a.m. Eastern Time. Hosting the call from the company will be Rory Byrne, Chief Executive Officer; Johan Lindén, Chief Operating Officer; Frank Davis, Chief Financial Officer; and James O'Regan, Head of Investor Relations.

A presentation to accompany the discussion will be posted on www.doleplc.com/investors.

To access the webcast, go to “Events and Presentations” at www.doleplc.com/investors. An archived replay of the webcast will also be available shortly after the live event has concluded.

The conference call can be accessed live by dialling +1 646 787 9445 or for international callers by dialling +44 203 936 2999. The access code is 710667.

A replay of the call will be available through May 31, 2022, by dialling +1 845 709 8569, or for international callers by dialling +44 203 936 3001. The replay access code is 039478.

About Dole plc:

A global leader in fresh produce, Dole Plc grows, markets, and distributes an extensive variety of fresh fruits and vegetables sourced locally and from around the world. Dedicated and passionate in exceeding our customers’ requirements in over 75 countries, our goal is to make the world a healthier and a more sustainable place.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220427005521/en/

Investor Contact:
James O’Regan, Head of Investor Relations, Dole plc
[email protected]
+353 1 887 2794

Media Contact:
Phil Elwood, Ogilvy
[email protected]
+1 202 423 7957

Brian Bell, Ogilvy
[email protected]
+353 87 2436 130

Source: Dole plc

You May Also Be Interested In

• Micron offers Taiwan workers up to 68-month bonuses as strike threat looms
• KBRA Assigns Preliminary Ratings to AHMC 2026-CNF1 Trust
• Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)